Hong Kong makes belated bid to build biotech business

As Hong Kong belatedly wakes up to the benefits of biotechnology, Singapore streaks ahead.

Toni Clarke

September 29, 2000

More than a year after Singapore announced it would invest $1 billion to cultivate start-up biotechnology companies and make life sciences one of the main pillars of its economy, Hong Kong is finally taking action to catch up.

The government's Innovation and Technology Commission has put together a team headed by Sir Colin Dollery, senior consultant to SmithKline Beecham, to study Hong Kong's resources and make recommendations on how it can best take advantage of the genetic revolution.

Sign In to Your Account To Access Exclusive FinanceAsia Content!

Please sign in to your subscription to unlock full access to our premium FA resources.

Free Registration & 7-Day Trial
Register now to enjoy a 7-day free trial - no registration fees required. Click the link to get started.

Note: This free trial is a one-time offer.

Questions?
If you have any enquiries or would like a quote for a team or company licence, please contact us at [email protected]. Our subscription team will be happy to assist you.